Poster Presentations

Maroun Bou Zerdan, MD

• Abstract
• Poster

Isabel Houlzet, PharmD, BCOP, BCPS (Pfizer)

• Poster

Jamila Mammadova

• Abstract
• Poster

Claudia Martin Diaz, PharmD, BCPS

• Abstract
• Poster

Elizabeth N. Osmon, PharmD, BCPS

• Abstract
• Poster

Jennifer Sibley, Bristol-Myers Squibb (2)

• Abstract #1
• Abstract #2
• Poster #1
• Poster #2

Ollie Annum, PharmD

• Abstract

Monica Sawiris and Taylor Chou, M.M.S.

• Abstract

Nadeem Bilani, MD (2)

• Abstract
• Poster #1
• Poster #2

Jamie Noll, Puma Biotechnology (2)

• Abstract #1
• Abstract #2

 

FINAL ATTENDEE LIST

Thank you, Spring Session Exhibitors In-person and Virtual!

AbbVie Pharmaceuticals

Acceleron Pharma

Acrotech Biopharma

Adaptive Biotechnologies

ADC Therapeutics

AdventHealth

Alexion Pharmaceuticals

Alnylam Pharmacuticals

AMAG Pharmaceuticals

Amgen Oncology

Apellis

Astellas Pharma

AstraZeneca

Bayer

BeiGene

Blue Earth Diagnostics

Blueprint Medicines

Boehringer Ingelheim

Bristol-Myers Squibb

Cancer Expert Now

Caris Life Sciences

Clovis Oncology

Coherus Biosciences

Daiichi Sankyo

Deciphera

Dova Pharmaceuticals

Eisai

EMD Serono

Epizyme

Exelixis

Foundation Medicine

Genentech

Gilead

GlaxoSmithKline

Guardant Health

Heme Onc Call

Heron Therapeutics

Humana Specialty Pharmacy

Incyte

IPSEN Biopharmaceuticals

Jazz Pharmaceuticals

Johnson & Johnson

Karyopharm Therapeutics

Kite, A Gilead Company

Kyowa Kirin

Lilly Oncology

Merck

Moffitt Cancer Center

MorphoSys

Natera

NeoGenomics

Novartis

Oncology Supply

Oncopeptides

Pfizer Oncology

Pharmacosmos Therapeutic

Pharmacyclics

ProAssurance

Puma Biotechnology

Regeneron

Rigel Pharmaceuticals

Sandoz, a Novartis Company

Sanofi Genzyme

SeaGen

Servier Pharmaceuticals

Taiho Oncology

Takeda Oncology

Tempus

Teva Pharmaceuticals

TG Therapeutics

Tolmar Pharmaceuticals

UF Health Cancer Center

Viatris

ZYNO Solutions

Thank you for your support of FLASCO !

 

Gaylord Palms Resort & Convention Center

6000 W. Osceola Parkway, Kissimmee, FL 34746

 

The FLASCO Business of Oncology Summit and Spring Session program has been approved for continuing education credit. The Medical Educator Consortium has approved a maximum of 10.25 hours CME/CE for the participation of April 16 and April 17 programs. A link to the evaluation survey will be emailed to you after the conference. Please complete the survey within the allotted time. Add info@meccinc.com to your contacts to ensure receipt. Your certificate of attendance will be emailed to you for download immediately after completion/submission of survey.

Accreditation and Credit Statements

In support of improving patient care, this activity has been planned and implemented by the Medical Educator Consortium and the Florida Society of Medical Oncology.  The Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 10.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician – The Medical Educator Consortium designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing – The Medical Educator Consortium designates this activity for 10.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

Pharmacist – This Application based activity has been approved for 10.25 contact hours (1.0 CEUs) by the Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-9999-20-019-L01-P.  Your CE credits will be electronically submitted to CPE Monitor^® within 60 days upon successful completion of the activity.

Physician Assistant The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 10.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure Policy – The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content.  MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners.  The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.  CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession. 

Disclosure of Unlabeled Use – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

Disclaimer – Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.                                       

Accredited by             

Shared PowerPoints

• Cancer Disparities – Dr. Alvarado
• Cancer Disparities – Dr. Fu
• Cancer Disparities – Dr. Gralow
• Cancer Disparities – Dr. Polite
• Updates in Diffuse Large B-cel Lymphoma – Dr. Chavez
• Updates in CAR-T Therapies for DLBCL – Dr. Komanduri
• Solid Tumor – Dr. Sonpavde
• Solid Tumor – Dr. Cusnir
• Solid Tumor – Dr. Gralow TNBC
• Solid Tumor – Dr. Raez

IF PARTICIPATING VIRTUALLY Please log into the Engagez website to view the live stream. The Business of Oncology Summit, some of the FLASCO Foundation Gala, and the Spring Session scientific discussions will be streamed for online viewing. If  your registration was confirmed you will have access to view the Business of Oncology Summit. As a FLASCO Corporate or general member, you will have access to the Spring Session scientific discussions. The FLASCO Business of Oncology and Spring Session will be live Thursday, April 15, at 6:00pm. Please log in and peruse the online conference. Be sure to visit the exhibit showcase. The more you engage the better your opportunity to win!